"
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies"
written by Kenneth Blum, Igor Elman, David Han, Colin Hanna, David Baron, Ashim Gupta, Shan Kazmi, Jag Khalsa, Debasis Bagchi, Thomas McLaughlin, Rajendra D. Badgaiyan, Edward J. Modestino, Drew Edwards, Catherine A. Dennen, Eric R. Braverman, Abdalla Bowirrat, Keerthy Sunder, Kevin Murphy, Nicole Jafari, Foojan Zeine, Paul R. Carney, Mark S. Gold, Kai-Uwe Lewandowski, Alireza Sharafshah, Aryeh R. Pollack, Panayotis K. Thanos,
published by
Open Journal of Immunology,
Vol.14 No.3, 2024
has been cited by the following article(s):